ArticleBlood2024

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.

Hrishikesh Srinagesh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.